他克莫司市场规模 - 按产品类型（注射、片剂和胶囊、软膏、颗粒）、按应用（皮肤炎、免疫抑制）、最终用途（医院、专科诊所）和预测，2024 - 2032 年

由于患者对非类固醇药物的偏好不断增加，他克莫司市场规模预计在 2024 年至 2032 年期间以 5.6% 的复合年增长率扩大。他克莫司为湿疹、牛皮癣和皮肤炎等疾病提供了一种非类固醇替代品，降低了类固醇相关副作用的风险。他克莫司软膏、霜剂和其他外用剂型的推出为皮肤病提供了有针对性的有效治疗。透过改进配方以确保更好的吸收和功效，製药公司正在扩大其他克莫司产品线，以满足对非类固醇药物不断增长的需求。举个例子，2023年8月，製药公司Glenmark Pharmaceuticals Ltd.的0.03%他克莫司软膏获得美国FDA最终批准。

此外，老年人更容易受到器官移植排斥和自体免疫疾病的影响，增加了对他克莫司治疗的需求。随着年龄相关的免疫功能下降，他克莫司对于管理移植结果和自体免疫疾病也变得至关重要。需要长期免疫抑制治疗的老年患者数量不断增加也推动了市场的扩张。

他克莫司产业分为产品类型、应用、最终用途和地区。

就产品类型而言，片剂和胶囊细分市场的市场规模在2023年产生了可观的收入，预计2024年至2032年的增长率为6.1%，这归因于其易于使用和精确剂量而受到消费者越来越多的青睐。他克莫司片剂和胶囊为器官移植受者的免疫抑制和各种自体免疫疾病的治疗提供了方便的口服给药方式。随着配方技术的进步确保更好的生物利用度和稳定性，他克莫司片剂和胶囊预计将获得巨大的吸引力。

根据应用情况，由于皮肤病患病率不断上升，加上人们对治疗技术有效性的认识不断提高，预计到 2032 年，皮肤炎领域的他克莫司产业复合年增长率将达到 5.5%。他克莫司在治疗各种形式的皮肤炎方面显示出显着的疗效，包括异位性皮肤炎和接触性皮肤炎。它具有减少发炎和瘙痒的能力，成为皮肤病的首选。此外，增加患者对副作用较少的非类固醇药物的偏好将进一步促进该细分市场的成长。

考虑到区域格局，由于该地区器官移植流行率上升、自体免疫疾病发病率增加以及医疗基础设施改善，亚太地区他克莫司产业预计在 2024 年至 2032 年期间复合年增长率为 6.2%。庞大的人口基数和不断增长的需要免疫抑制治疗的老年人口正在推动对他克莫司的需求。此外，政府为改善医疗保健的可及性和他克莫司仿製药的供应而采取的倡议可能会加速该地区的行业扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 器官移植手术数量不断增加
    • 自体免疫疾病盛行率上升
    • 免疫抑制研究和开发活动激增
  • 产业陷阱与挑战
    • 副作用和替代疗法的可用性
• 成长潜力分析
• 监管环境
• 报销场景
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

• 主要趋势
• 注射
• 片剂和胶囊
• 药膏
• 颗粒剂

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 皮肤炎
• 免疫抑制
• 其他应用

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 专科诊所
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Abbott Laboratories
• Astellas Pharma Inc.
• Biocon Ltd.
• F. Hoffmann-La Roche Ltd
• Glenmark Pharmaceuticals Inc.
• GSK plc
• Lupin Pharmaceuticals Ltd.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Viatris Inc.

Tacrolimus Market size is poised to expand at 5.6% CAGR between 2024-2032 due to increasing patient preference for non-steroidal options. Tacrolimus offers a non-steroidal alternative for conditions like eczema, psoriasis, and dermatitis, reducing the risk of steroid-related side effects. The introduction of Tacrolimus ointments, creams, and other topical forms provides targeted and effective treatment for skin conditions. With improved formulations for ensuring better absorption and efficacy, pharmaceutical companies are expanding their Tacrolimus product lines for meeting the rising demand for non-steroidal options. To cite an instance, in August 2023, Glenmark Pharmaceuticals Ltd., a pharmaceutical company received the final U.S. FDA approval for its Tacrolimus ointment 0.03 percent.

Furthermore, elderly individuals are more susceptible to organ transplant rejection and autoimmune diseases, increasing the demand for Tacrolimus therapy. With age-related decline in immune function, Tacrolimus has also emerged crucial for managing transplant outcomes and autoimmune conditions. The rising number of elderly patients requiring long-term immunosuppressive therapy is also boosting the market expansion.

The tacrolimus industry is segmented into product type, application, end-use, and region.

In terms of product type, the market size from the tablets and capsules segment generated substantial revenue in 2023 and is estimated to depict a 6.1% growth rate from 2024-2032 attributed to the increasing consumer preference due to their ease of use and precise dosage. Tacrolimus tablets and capsules offer convenient oral administration for immunosuppression in organ transplant recipients and the treatment of various autoimmune disorders. With advancements in formulation technology for ensuring better bioavailability and stability, tacrolimus tablets and capsules are expected to gain significant traction.

Based on application, the tacrolimus industry from the dermatitis segment is projected to witness 5.5% CAGR through 2032 driven by the rising prevalence of skin disorders coupled with the increasing awareness about the effectiveness of the treatment techniques. Tacrolimus has shown remarkable efficacy in treating various forms of dermatitis, including atopic dermatitis and contact dermatitis. It has the ability to reduce inflammation and itching, emerging as a preferred choice for dermatological conditions. Additionally, increasing patient preference for non-steroidal options with fewer side effects will further boost the segment growth.

Given the regional landscape, the Asia Pacific tacrolimus industry is set to exhibit 6.2% CAGR during 2024-2032 owing to the rising prevalence of organ transplantations, increasing incidences of autoimmune diseases, and improving healthcare infrastructure across the region. The large population base and the growing geriatric population requiring immunosuppressive therapy are fueling the demand for tacrolimus. Additionally, government initiatives to improve access to healthcare and the availability of generic versions of Tacrolimus are likely to accelerate the regional industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing number of organ transplant procedures
    • 3.2.1.2 Rising prevalence of autoimmune diseases
    • 3.2.1.3 Surge in immunosuppressive research and development activities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and the availability of the alternative treatments
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Technological landscape
• 3.7 Porter's analysis
  • 3.7.1 Supplier power
  • 3.7.2 Buyer power
  • 3.7.3 Threat of new entrants
  • 3.7.4 Threat of substitutes
  • 3.7.5 Industry rivalry
• 3.8 PESTEL analysis
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injections
• 5.3 Tablets and capsules
• 5.4 Ointments
• 5.5 Granules

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Dermatitis
• 6.3 Immunosuppression
• 6.4 Other applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Astellas Pharma Inc.
• 9.3 Biocon Ltd.
• 9.4 F. Hoffmann-La Roche Ltd
• 9.5 Glenmark Pharmaceuticals Inc.
• 9.6 GSK plc
• 9.7 Lupin Pharmaceuticals Ltd.
• 9.8 Novartis AG
• 9.9 Pfizer Inc.
• 9.10 Takeda Pharmaceutical Company Limited
• 9.11 Viatris Inc.